Cizzle Biotechnology is now in commercial motion, with its lung cancer diagnostic test entering clinical validation across North America. Backed by Cizzle Bio, OmniHealth, and the Moffitt Cancer Center, the company is moving from lab bench to nationwide rollout — with royalty payments already in hand...
Avingtrans CEO Steve McQuillan shares how AI, energy and infrastructure megatrends are driving record results — and why strategic deals could be back on the table in FY26...
Vassilios Carellas breaks down the latest performance from Kiln 1, explains what’s unlocking new revenue from previously discarded material, and reveals how a low-cost hydration circuit could unlock even more premium product lines...
Acuity RM CEO David Rajakovich reveals how a leaner, AI-native Acuity is chasing profitability and reshaping the cybersecurity risk landscape, from ISO certifications to vendor threat management...
Group CEO Douglas Grant shares why now is the moment for this bold fintech move, offering short-term lending products tailor-made for consumers and SMEs squeezed by the ongoing cost-of-living crisis..
CEO James Hickman outlines how the company’s investment-heavy first half is already unlocking upside, with Dubai now firmly established as a high-potential hub and Canada stepping into revenue generation...
Executive Chairman Stephen West explains how AO-252, Coiled’s first-in-class oncology asset, could reshape Roquefort’s pipeline, transform shareholder value, and set the stage for an AIM relist with an eye on NASDAQ..
CEO, Enkhmaral Batkhuyag, shares how the company is leveraging advanced technology to transform microfinance in Central Asia, scale into new markets, and break ground with digital insurance...
CEO Tony Brewer outlines how the flooring distributor is pushing beyond its £160m run rate, growing like-for-like sales by over 10%, and doubling its dividend since 2021...
Cora Gold CEO Bert Monro outlines the company’s updated Sanankoro DFS — with a 26% reserve boost, rapid 1.1-year payback, and a hybrid solar plan set to cut costs and emissions...
XP Factory just posted a 30% jump in EBITDA, with both Escape Hunt and Boom Battle Bar gaining ground. CEO Richard Harpham sets out the roadmap to £100m in sales and 50%+ capital returns. High margins, high growth — and a compelling investor case...
Mark Thomas of Hardman & Co explains why Arbuthnot’s profit drop isn’t the full story — and where the real value creation is happening across its wealth, deposits, and specialist lending arms...
CEO Graeme Purdy shares a pivotal update on the company’s Stereax micro batteries as they complete manufacturing qualification and move into production...
EDX Medical Group Plc has joined forces with leading NHS and government health bodies to deliver a rapid hospital-acquired pneumonia test. Sir Chris Evans explains why this partnership could change patient outcomes, cut costs, and accelerate the UK’s precision medicine agenda...
TEAM plc Executive Chairman Mark Clubb has given an interview with DirectorsTalk, outlining the firm’s UCITS fund launch, HY25 interim results, and future outlook...
Cizzle Biotechnology is now in commercial motion, with its lung cancer diagnostic test entering clinical validation across North America. Backed by Cizzle Bio, OmniHealth, and the Moffitt Cancer Center, the company is moving from lab bench to nationwide rollout — with royalty payments already in hand...
Avingtrans CEO Steve McQuillan shares how AI, energy and infrastructure megatrends are driving record results — and why strategic deals could be back on the table in FY26...
Vassilios Carellas breaks down the latest performance from Kiln 1, explains what’s unlocking new revenue from previously discarded material, and reveals how a low-cost hydration circuit could unlock even more premium product lines...
Acuity RM CEO David Rajakovich reveals how a leaner, AI-native Acuity is chasing profitability and reshaping the cybersecurity risk landscape, from ISO certifications to vendor threat management...
Group CEO Douglas Grant shares why now is the moment for this bold fintech move, offering short-term lending products tailor-made for consumers and SMEs squeezed by the ongoing cost-of-living crisis..
CEO James Hickman outlines how the company’s investment-heavy first half is already unlocking upside, with Dubai now firmly established as a high-potential hub and Canada stepping into revenue generation...
Executive Chairman Stephen West explains how AO-252, Coiled’s first-in-class oncology asset, could reshape Roquefort’s pipeline, transform shareholder value, and set the stage for an AIM relist with an eye on NASDAQ..
CEO, Enkhmaral Batkhuyag, shares how the company is leveraging advanced technology to transform microfinance in Central Asia, scale into new markets, and break ground with digital insurance...
CEO Tony Brewer outlines how the flooring distributor is pushing beyond its £160m run rate, growing like-for-like sales by over 10%, and doubling its dividend since 2021...
Cora Gold CEO Bert Monro outlines the company’s updated Sanankoro DFS — with a 26% reserve boost, rapid 1.1-year payback, and a hybrid solar plan set to cut costs and emissions...
XP Factory just posted a 30% jump in EBITDA, with both Escape Hunt and Boom Battle Bar gaining ground. CEO Richard Harpham sets out the roadmap to £100m in sales and 50%+ capital returns. High margins, high growth — and a compelling investor case...
Mark Thomas of Hardman & Co explains why Arbuthnot’s profit drop isn’t the full story — and where the real value creation is happening across its wealth, deposits, and specialist lending arms...
CEO Graeme Purdy shares a pivotal update on the company’s Stereax micro batteries as they complete manufacturing qualification and move into production...
EDX Medical Group Plc has joined forces with leading NHS and government health bodies to deliver a rapid hospital-acquired pneumonia test. Sir Chris Evans explains why this partnership could change patient outcomes, cut costs, and accelerate the UK’s precision medicine agenda...
TEAM plc Executive Chairman Mark Clubb has given an interview with DirectorsTalk, outlining the firm’s UCITS fund launch, HY25 interim results, and future outlook...
